Skip to main content

Treatment Clinical Trials for Neuroblastoma

Review the neuroblastoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-46 of 46

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Status: Active
Location: 2 locations
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Iobenguane I-131 in Treating Patients with Recurrent Neuroblastoma, Malignant Pheochromocytoma, or Malignant Paraganglioma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
TGFbeta-imprinted Natural Killer Cells in Combination with Irinotecan, Temozolomide, and Dinutuximab for the Treatment of Patients with Relapsed or Refractory Neuroblastoma, Allo-STING Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
PEEL-224 Alone and in Combination with Vincristine and Temozolomide for the Treatment of Refractory, Progressive, or Relapsed Childhood Solid Tumors, Neuroblastoma or Rhabdomyosarcoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
GPC2-Directed Chimeric Antigen Receptor T Cells for the Treatment of Patients with Relapsed or Refractory Neuroblastoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
RhIL-15 with Dinutuximab, Irinotecan and Temozolomide for the Treatment of Children and Young Adults with Relapsed or Refractory Neuroblastoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Status: Active
Location: 2 locations
PHOX2B Peptide-Centric Chimeric Antigen Receptor Autologous T cells for the Treatment of Relapsed or Refractory Neuroblastoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors
Status: Active
Location: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Use of Virtual Reality for Surgical Planning in Neuroblastoma
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Status: Active
Location: See ClinicalTrials.gov
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults with Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
Status: Temporarily Closed to Accrual
Location: 6 locations
A Study of EGFR806 CAR T-Cell Immunotherapy for Treating Children and Young Adults with Recurrent/Refractory Solid Tumors
Status: Temporarily Closed to Accrual
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Iobenguane I-131 in Treating Patients with Recurrent or Refractory Neuroblastoma or Non-neuroblastic Iobenguane Avid Tumors
Status: Temporarily Closed to Accrual and Intervention
Location: See ClinicalTrials.gov